MAIN


1996-2019. All Rights Reserved. Online Journal of Bioinformatics . You may not store these pages in any form except for your own personal use. All other usage or distribution is illegal under international copyright treaties. Permission to use any of these pages in any other way besides the before mentioned must be gained in writing from the publisher. This article is exclusively copyrighted in its entirety to OJB publications. This article may be copied once but may not be, reproduced or re-transmitted without the express permission of the editors. This journal satisfies the refereeing requirements (DEST) for the Higher Education Research Data Collection (Australia). Linking:To link to this page or any pages linking to this page you must link directly to this page only here rather than put up your own page.


OJBTM

Online Journal of Bioinformatics

Volume 14 (2): 138-145, 2013


Subtractive genomic identification of drug targets in Leishmania Donovani and L. Infantum.

 

Tanima Shree (MSc)1, Suhail Ahmad Khan (B.Tech)2, Shivanjali Saxena (B.Tech)3.

 

1Institute of Computational Biology, Domlur Layout, Bangalore, Karnataka, 2,3Amity University Campus, Malhaur, Gomti Nagar Extension, Lucknow, Uttar Pradesh, India.

 

ABSTRACT

 

Shree T, Khan SA, Saxena S., Subtractive Genomic identification of drug targets in Leishmania Donovani and Infantum, Onl J Bioinform., 14(2):138-145, 2013. Subtractive genomics can identify genes essential to a human parasite not present in a host to identify drug targets against Leishmania spp. Three potential proteins in Leishmania Donovani and Infantum are described which did not share sequence homology to human proteins when compared against genes present in the Database of Essential Genes. Glyoxylase II and 2-Hydroxymethyl-5-(7-methylamino-imidazol[4,5-b]pyridin-3-yl)-tetrahydro-furan-3-ol(HEMBL405920) were identified as targets in Leishmania infantum which bind to non-conserved residues in the human enzyme.

 

Keywords: Subtractive genomics, Leishmaniasis, Virtual screening, Kala-azar, Therapeutic targets, Sub-cellular location.


MAIN

 

FULL-TEXT (SUBSCRIBE OR PURCHASE TITLE $25USD)